Safety and immunogenicity of a single dose, live-attenuated ‘tetravalent dengue vaccine’ in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial

BACKGROUND: Dengue fever is the most prevalent mosquito-borne viral disease in the world, with 390 million dengue infections occurring every year. There is an unmet medical need to develop a safe, effective and affordable dengue vaccine against all four Dengue serotype viruses-DENV1, DENV-2, DENV-3...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohanty, Lalitendu, Prabhu, Madhav, Kumar Mishra, Amit, Purty, Anil J, Kanungo, Reba, Ghosh, Goutam, Prahan Kumar, R, Newton Raj, A., Bhushan, Sumit, Kumar Jangir, Manoj, Gupta, Anu, Bhakri, Anju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892502/
https://www.ncbi.nlm.nih.gov/pubmed/35252836
http://dx.doi.org/10.1016/j.jvacx.2022.100142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892502/
https://www.ncbi.nlm.nih.gov/pubmed/35252836
http://dx.doi.org/10.1016/j.jvacx.2022.100142

Ejemplares similares